- Current report filing (8-K)
December 16 2009 - 1:50PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities Exchange Act of
1934
Date
of report (Date of earliest event reported):
December 16, 2009
BIOSTAR
PHARMACEUTICALS, INC.
(Exact
name of registrant as specified in Charter)
Maryland
|
|
333-147363
|
|
20-5101287
|
(State
or other jurisdiction of
incorporation
or organization)
|
|
(Commission
File No.)
|
|
(IRS
Employer Identification No.)
|
No.
588 Shiji Avenue
Xiangyang
City, Shaanxi Province
People’s
Republic of China 712046
(Address
of Principal Executive Offices)
86-029-33686638
(Issuer Telephone
Number)
N/A
(Former name or
former address, if changed since last report)
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
o
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
o
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
o
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
o
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
On
December 16, 2009, Biostar Pharmaceuticals, Inc. issued a press release, a copy
of which is attached hereto as Exhibit 99.1, and the information in Exhibit 99.1
is incorporated herein by reference.
The
information in Item 8.01 and Item 9.01(d) in this Current Report on Form 8-K and
the exhibit attached hereto shall not be deemed “filed” for the purpose of
Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise
subject to the liabilities of that Section, nor shall it be deemed incorporated
by reference into any filing under the Securities Act of 1933, as amended, or
the Securities Exchange Act of 1934, as amended, except as expressly set forth
by specific reference in such a filing.
Item
9.01
|
Financial
Statements and Exhibits
|
(d) Exhibits
Exhibit
Number
|
|
Description
|
|
|
|
99.1
|
|
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has
duly caused this report to be signed on its behalf by the undersigned thereunto
duly authorized.
Date: December
16, 2009
|
Biostar
Pharmaceuticals, Inc.
(Registrant)
|
|
|
|
|
By:
|
/s/
Elaine
Zhao
|
|
Elaine
Zhao
|
|
Chief
Financial Officer
|
Biostar Pharmaceuticals (CE) (USOTC:BSPM)
Historical Stock Chart
From Jun 2024 to Jul 2024
Biostar Pharmaceuticals (CE) (USOTC:BSPM)
Historical Stock Chart
From Jul 2023 to Jul 2024